New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
06:27 EDTRIGLRigel Pharmaceuticals called a 2014 'sleeper pick' at Jefferies
Jefferies calls Rigel Pharmaceuticals its 2014 "sleeper pick" saying investors are overlooking the potential of fostamatinib in immune thrombocytopenic purpura. The firm believes fostamatinib is "highly likely" to succeed and raised its price target for Rigel to $10 from $6.
News For RIGL From The Last 14 Days
Check below for free stories on RIGL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 16, 2014
07:31 EDTRIGLRigel Pharmaceuticals initiates Phase 3 studies of fostamatinib in ITP
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use